Sasaki Akinori, Masuda Shuko, Yoshioka Tsubasa, Saito Akira, Motomura Yasuaki
Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, JPN.
Pathology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, JPN.
Cureus. 2024 Jan 22;16(1):e52765. doi: 10.7759/cureus.52765. eCollection 2024 Jan.
Breast cancer often metastasizes to the lungs, bones, liver, and brain; however, gastric and colonic metastases from breast cancer are rare. Nevertheless, here, we present the case of a 50-year-old woman diagnosed with recurrent breast cancer, exhibiting gastric and colonic metastases that were detected when she experienced intermittent abdominal pain. The differentiation between primary gastric cancer and metastasis from breast cancer was made through immunohistochemical staining. The patient underwent treatment with palbociclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, and anastrozole, with no significant adverse effects. Subsequent upper and lower endoscopic examinations following the initiation of these treatments revealed tumor shrinkage in both gastric and colonic metastases. This case report presents the first instance in which morphological changes in gastrointestinal metastasis induced by CDK4/6 inhibitors could be evaluated.
乳腺癌常转移至肺、骨、肝和脑；然而，乳腺癌的胃和结肠转移很少见。尽管如此，在此我们报告一例50岁女性，被诊断为复发性乳腺癌，出现胃和结肠转移，在她经历间歇性腹痛时被检测到。通过免疫组织化学染色区分原发性胃癌和乳腺癌转移。该患者接受了细胞周期蛋白依赖性激酶（CDK）4/6抑制剂哌柏西利和阿那曲唑治疗，无明显不良反应。开始这些治疗后随后的上下内镜检查显示胃和结肠转移瘤均缩小。本病例报告展示了首次能够评估CDK4/6抑制剂诱导的胃肠道转移形态学变化的实例。
